j&j featured image
News Pharmaceutical & Biotech Stories

Johnson & Johnson Starts Two-Dose Trial COVID-19 Vaccine on U.K

Monday, November 16, Johnson & Johnson launched a new late-stage trial in Britain to test two-dose regimen of its COVID-19 candidate vaccine.

The UK arm of the study is aiming to recruit 6,000 participants among a total of 30,000 people globally, scientists leading the UK trial said. Volunteers will be recruited at 17 sites across the UK.

They will be given the first dose of either a placebo or the experimental shot, currently called Ad26COV2, followed by a second dose or placebo 57 days later, said Saul Faust, a professor of pediatric immunology and infectious diseases who is co-leading the trial at the University Hospital Southampton.

If the results of the single-shot trial are positive, the company said it could simplify the distribution of millions of doses compared with leading rivals requiring two doses. The efficacy of a double-dose vaccine could be affected if people fail to return to get their second shot.

ASEAN HR TECH VENTURE SUMMIT 2018
REGISTER NOW 33% DISCOUNT
SUMMIT PASS